<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="cncr35680" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Cancer</journal-id><journal-id journal-id-type="pmc-domain-id">379</journal-id><journal-id journal-id-type="pmc-domain">blackwellopen</journal-id><journal-id journal-id-type="publisher-id">CNCR</journal-id><journal-title-group><journal-title>Cancer</journal-title></journal-title-group><issn pub-type="ppub">0008-543X</issn><issn pub-type="epub">1097-0142</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Wiley Open Access Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11696210</article-id><article-id pub-id-type="pmcid-ver">PMC11696210.1</article-id><article-id pub-id-type="pmcaid">11696210</article-id><article-id pub-id-type="pmcaiid">11696210</article-id><article-id pub-id-type="pmid">39748726</article-id><article-id pub-id-type="doi">10.1002/cncr.35680</article-id><article-id pub-id-type="publisher-id">CNCR35680</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>ORIGINAL ARTICLE</subject><subj-group subj-group-type="heading"><subject>Discipline</subject><subj-group subj-group-type="heading"><subject>Clinical Trials</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>A trial of radiolabeled antibody yttrium&#8208;90&#8211;FF&#8208;21101 for the treatment of advanced ovarian and other cancers</article-title><alt-title alt-title-type="right-running-head">90Y&#8211;FF&#8208;21101 trial for cancer treatment</alt-title></title-group><contrib-group><contrib id="cncr35680-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Mahalingam</surname><given-names initials="D">Devalingam</given-names></name><degrees>MD, PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2979-9894</contrib-id><xref rid="cncr35680-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>mahalingam@nm.org</email></address></contrib><contrib id="cncr35680-cr-0002" contrib-type="author"><name name-style="western"><surname>Owonikoko</surname><given-names initials="TK">Taofeek K.</given-names></name><degrees>MD, PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7724-7728</contrib-id><xref rid="cncr35680-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="cncr35680-curr-0001" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="cncr35680-cr-0003" contrib-type="author"><name name-style="western"><surname>Delpassand</surname><given-names initials="E">Ebrahim</given-names></name><degrees>MD, PhD</degrees><xref rid="cncr35680-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="cncr35680-cr-0004" contrib-type="author"><name name-style="western"><surname>Mulcahy</surname><given-names initials="MF">Mary F.</given-names></name><degrees>MD</degrees><xref rid="cncr35680-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cncr35680-cr-0005" contrib-type="author"><name name-style="western"><surname>Kalyan</surname><given-names initials="A">Aparna</given-names></name><degrees>MD</degrees><xref rid="cncr35680-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cncr35680-cr-0006" contrib-type="author"><name name-style="western"><surname>Ulahannan</surname><given-names initials="S">Susanna</given-names></name><degrees>MD</degrees><xref rid="cncr35680-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="cncr35680-cr-0007" contrib-type="author"><name name-style="western"><surname>Cheung</surname><given-names initials="K">Kin</given-names></name><degrees>PhD</degrees><xref rid="cncr35680-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="cncr35680-cr-0008" contrib-type="author"><name name-style="western"><surname>Izumi</surname><given-names initials="Y">Yasayuki</given-names></name><degrees>MEng</degrees><xref rid="cncr35680-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="cncr35680-cr-0009" contrib-type="author"><name name-style="western"><surname>Johansen</surname><given-names initials="M">Mary</given-names></name><degrees>PharmD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0118-2224</contrib-id><xref rid="cncr35680-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="cncr35680-cr-0010" contrib-type="author"><name name-style="western"><surname>Madden</surname><given-names initials="T">Timothy</given-names></name><degrees>PharmD</degrees><xref rid="cncr35680-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="cncr35680-cr-0011" contrib-type="author"><name name-style="western"><surname>Shimoyama</surname><given-names initials="S">Susumu</given-names></name><degrees>MS</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0584-5200</contrib-id><xref rid="cncr35680-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="cncr35680-cr-0012" contrib-type="author"><name name-style="western"><surname>Subach</surname><given-names initials="RA">Ruth Ann</given-names></name><degrees>PharmD</degrees><xref rid="cncr35680-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="cncr35680-cr-0013" contrib-type="author"><name name-style="western"><surname>Suzuki</surname><given-names initials="T">Takeaki</given-names></name><degrees>PhD</degrees><xref rid="cncr35680-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="cncr35680-cr-0014" contrib-type="author" corresp="yes"><name name-style="western"><surname>Wages</surname><given-names initials="DS">David S.</given-names></name><degrees>MD, PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7407-6727</contrib-id><xref rid="cncr35680-aff-0005" ref-type="aff">
<sup>5</sup>
</xref><xref rid="cncr35680-curr-0002" ref-type="aff">
<sup>7</sup>
</xref><address><email>david@docwages.com</email></address></contrib><contrib id="cncr35680-cr-0015" contrib-type="author"><name name-style="western"><surname>Wheeler</surname><given-names initials="C">Catherine</given-names></name><degrees>MD</degrees><xref rid="cncr35680-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="cncr35680-cr-0016" contrib-type="author"><name name-style="western"><surname>Richardson</surname><given-names initials="DL">Debra L.</given-names></name><degrees>MD</degrees><xref rid="cncr35680-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib></contrib-group><aff content-type="private-address" id="cncr35680-aff-0001">
<label>
<sup>1</sup>
</label>
<institution>Northwestern University Feinberg School of Medicine</institution>
<city>Chicago</city>
<named-content content-type="country-part">Illinois</named-content>
<country country="US">USA</country>
</aff><aff content-type="private-address" id="cncr35680-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>Winship Cancer Institute, Emory University</institution>
<city>Atlanta</city>
<named-content content-type="country-part">Georgia</named-content>
<country country="US">USA</country>
</aff><aff content-type="private-address" id="cncr35680-aff-0003">
<label>
<sup>3</sup>
</label>
<institution>Excel Diagnostics and Nuclear Oncology Center</institution>
<city>Houston</city>
<named-content content-type="country-part">Texas</named-content>
<country country="US">USA</country>
</aff><aff content-type="private-address" id="cncr35680-aff-0004">
<label>
<sup>4</sup>
</label>
<institution>Stephenson Cancer Center</institution>
<institution>University of Oklahoma Health Sciences Center/Sarah Cannon Research Institute</institution>
<city>Oklahoma City</city>
<named-content content-type="country-part">Oklahoma</named-content>
<country country="US">USA</country>
</aff><aff content-type="private-address" id="cncr35680-aff-0005">
<label>
<sup>5</sup>
</label>
<institution>FUJIFILM Pharmaceuticals USA, Inc</institution>
<city>Cambridge</city>
<named-content content-type="country-part">Massachusetts</named-content>
<country country="US">USA</country>
</aff><aff content-type="private-address" id="cncr35680-curr-0001"><label>
<sup>6</sup>
</label>Present address:
<institution>AbbVie GK</institution>
<city>Tokyo</city>
<country country="JP">Japan</country>
</aff><aff content-type="private-address" id="cncr35680-curr-0002"><label>
<sup>7</sup>
</label>Present address:
<institution>Deln3 Consulting LLC</institution>
<city>Southborough</city>
<postal-code>MA</postal-code>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Devalingam Mahalingam, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.<break/>
Email: <email>mahalingam@nm.org</email><break/>
David S. Wages, FUJIFILM Pharmaceuticals USA, Inc, Cambridge, MA, USA.<break/>
Email: <email>david@docwages.com</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>03</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="ppub"><day>01</day><month>1</month><year>2025</year></pub-date><volume>131</volume><issue seq="140">1</issue><issue-id pub-id-type="pmc-issue-id">478226</issue-id><issue-id pub-id-type="doi">10.1002/cncr.v131.1</issue-id><elocation-id>e35680</elocation-id><history><date date-type="rev-recd"><day>21</day><month>10</month><year>2024</year></date><date date-type="received"><day>19</day><month>6</month><year>2024</year></date><date date-type="accepted"><day>01</day><month>11</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>01</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>01</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-01-04 13:25:37.430"><day>04</day><month>01</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 FUJIFILM Pharmaceuticals U.S.A and The Author(s). <italic toggle="yes">Cancer</italic> published by Wiley Periodicals LLC on behalf of American Cancer Society.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="CNCR-131-0.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:CNCR-131-0.pdf"/><abstract><title>Abstract</title><sec id="cncr35680-sec-0001"><title>Background</title><p>Yttrium&#8208;90 FF&#8208;21101 (<sup>90</sup>Y&#8211;FF&#8208;21101) is a radiopharmaceutical that targets P&#8208;cadherin as a therapy against solid tumors. A previously reported, first&#8208;in&#8208;human study determined that a dose of 25 mCi/m<sup>2</sup> was safe, and a patient with clear cell carcinoma of the ovary achieved a complete response. In this article, the authors report the results of <sup>90</sup>Y&#8211;FF&#8208;21101 treatment in an ovarian carcinoma expansion cohort and in patients with selected solid tumors who had known high P&#8208;cadherin expression.</p></sec><sec id="cncr35680-sec-0002"><title>Methods</title><p>The trial was conducted as an open&#8208;label study in patients with advanced/metastatic disease. Radiologic response and safety were evaluated in patients who received 25 mCi/m<sup>2</sup> intravenously once every three cycles of 28 days until they developed progressive disease. Evaluation of the ovarian cohort was conducted in a Simon two&#8208;stage manner to determine further enrollment.</p></sec><sec id="cncr35680-sec-0003"><title>Results</title><p>Fifty&#8208;seven patients (20 with ovarian carcinoma) were enrolled and treated. Patients who had ovarian and solid tumors had received a median of five and three prior therapies, respectively. No complete or partial responses were observed, so the trial was ended. The median progression&#8208;free survival was 118 days for the ovarian cohort and 55 days for the solid&#8208;tumor cohort. The most common treatment&#8208;related adverse events were thrombocytopenia (40%) and neutropenia (54%). One patient each developed fatal veno&#8208;occlusive disease and intracranial hemorrhage. Patients with higher P&#8208;cadherin levels remained on the study longer.</p></sec><sec id="cncr35680-sec-0004"><title>Conclusions</title><p>
<sup>90</sup>Y&#8211;FF&#8208;21101 did not meet the predefined efficacy criteria, and adverse events were consistent with <sup>90</sup>Y agents. These data may assist in the development of other P&#8208;cadherin&#8211;directed therapies (ClinicalTrials.gov identifier <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02454010">NCT02454010</ext-link>).</p></sec></abstract><abstract abstract-type="short"><p>A clinical trial of yttrium&#8208;90&#8211;FF&#8208;21101 directed against P&#8208;cadherin did not meet predefined efficacy criteria. Because imaging studies indicated FF&#8208;21101 uptake by tumors, other warheads combined with P&#8208;cadherin&#8211;directed vehicles like FF&#8208;21101 may have greater success.</p></abstract><kwd-group><kwd id="cncr35680-kwd-0001">FF&#8208;21101</kwd><kwd id="cncr35680-kwd-0002">ovarian carcinoma</kwd><kwd id="cncr35680-kwd-0003">P&#8208;cadherin</kwd><kwd id="cncr35680-kwd-0004">radioimmunotherapy</kwd><kwd id="cncr35680-kwd-0005">radiopharmaceutical</kwd><kwd id="cncr35680-kwd-0006">solid tumor</kwd><kwd id="cncr35680-kwd-0007">yttrium&#8208;90 (<sup>90</sup>Y)</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>FUJIFILM Pharmaceuticals USA Inc.</funding-source></award-group></funding-group><counts><fig-count count="2"/><table-count count="3"/><page-count count="11"/><word-count count="6320"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>1 January 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.1 mode:remove_FC converted:03.01.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="self-citation" id="cncr35680-cit-0035"><string-name name-style="western"><surname>Mahalingam</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Owonikoko</surname><given-names>TK</given-names></string-name>, <string-name name-style="western"><surname>Delpassand</surname><given-names>E</given-names></string-name>, et al. <article-title>A trial of radiolabeled antibody yttrium&#8208;90&#8211;FF&#8208;21101 for the treatment of advanced ovarian and other cancers</article-title>. <source>Cancer</source>. <year>2025</year>;<elocation-id>e35680</elocation-id>. doi:<pub-id pub-id-type="doi">10.1002/cncr.35680</pub-id><pub-id pub-id-type="pmid">39748726</pub-id><pub-id pub-id-type="pmcid">PMC11696210</pub-id></mixed-citation>
</p></notes></front><body id="cncr35680-body-0001"><sec id="cncr35680-sec-0010"><title>INTRODUCTION</title><p>Monoclonal antibodies (mAbs) have been approved for cancer treatment for decades; however, single&#8208;agent mAb monotherapy has been variously successful.<xref rid="cncr35680-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="cncr35680-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="cncr35680-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> Cytotoxic chemicals and radionuclides have been used to arm mAbs to improve efficacy.<xref rid="cncr35680-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="cncr35680-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> Radiopharmaceutical therapy (RPT) uses a carrier molecule (typically an antibody) to selectively deliver radionuclides, primarily &#946; or &#945; emitters, to malignant cells without affecting tissues that lack the target antigen.<xref rid="cncr35680-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="cncr35680-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="cncr35680-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>
</p><p>RPT is effective against hematologic tumors. In patients with non&#8208;Hodgkin lymphoma, radiolabeled antibody conjugates at doses &lt;20 grays (Gy) demonstrated superior therapeutic efficacy over naked mAbs and efficacy comparable to that of combination cytotoxic drug regimens alone or combined with naked mAbs.<xref rid="cncr35680-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="cncr35680-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> Solid tumors are less radiosensitive than hematologic tumors, and the best RPT outcomes are in minimal disease settings.<xref rid="cncr35680-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="cncr35680-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="cncr35680-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> However, the approvals of &#946; emitters against neuroendocrine cancers and phaeochromocytomas and of an &#945; emitter against bone metastases of prostate cancer have reignited RPT development.</p><p>Potential RPT targets include the cadherin superfamily of transmembrane calcium&#8211;binding proteins involved in the formation of cell&#8208;to&#8208;cell adhesion. P&#8208;cadherin is particularly promising because it displays minimal expression in normal adult human tissues.<xref rid="cncr35680-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="cncr35680-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="cncr35680-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> Accordingly, P&#8208;cadherin&#8211;directed therapies have included unmodified mAbs, bispecific T&#8208;cell engagers, and antibody&#8211;drug combinations.<xref rid="cncr35680-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="cncr35680-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="cncr35680-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> Our approach was to develop the radiolabeled antibody yttrium&#8208;90 (<sup>90</sup>Y)&#8211;FF&#8208;21101 as an RPT agent.<xref rid="cncr35680-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="cncr35680-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> Its safety, tolerability, and antitumor activity in advanced solid tumors was investigated in a phase 1, first&#8208;in&#8208;human, dose&#8208;escalation trial (ClinicalTrials.gov identifier <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02454010">NCT02454010</ext-link>).<xref rid="cncr35680-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> As is standard for <sup>90</sup>Y agents, we used indium&#8208;111 (<sup>111</sup>In) imaging to investigate tumor localization and confirm radiation dosimetry to solid organs for safety.<xref rid="cncr35680-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> A favorable safety profile was observed for all tested doses of 5&#8211;25 mCi/m<sup>2</sup> in the 15 heavily pretreated patients. <sup>111</sup>In dosimetry results indicated that radiation doses were within all organ limits. After seven patients were treated with <sup>90</sup>Y&#8211;FF&#8208;21101, one patient with clear cell ovarian carcinoma developed a complete response (CR). Based on these results (completed in 2018), we began a dose&#8208;expansion phase in patients with ovarian carcinoma along with a separate exploratory cohort in patients with solid tumors known to overexpress P&#8208;cadherin. Herein, we present the final dose&#8208;expansion phase results for patients treated at the recommended phase 2 dose (25 mCi/m<sup>2</sup>).</p></sec><sec id="cncr35680-sec-0020"><title>MATERIALS AND METHODS</title><sec id="cncr35680-sec-0030"><title>Study design</title><p>The open&#8208;label expansion&#8208;phase study used a Simon 2&#8208;stage design to evaluate the ovarian carcinoma cohort (Figure&#160;<xref rid="cncr35680-fig-0001" ref-type="fig">1A</xref>) with the following parameters: if three or more of 15 patients had responses, the cohort added 13 additional patients (28 total). Enrollment beyond 15 patients was allowed during response evaluation. The exploratory cohort could enroll up to 80 patients with the following diseases: triple&#8208;negative breast cancer, head and neck squamous cell carcinoma, biliary cancer (cholangiocarcinoma or gallbladder carcinoma), pancreatic carcinoma, and colorectal cancer. These tumors were selected on the basis of their typically high P&#8208;cadherin expression, as measured by both gene and antigen expression.<xref rid="cncr35680-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="cncr35680-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> Because there are no validated criteria for minimal P&#8208;cadherin expression, it was not an entry criterion for the study. P&#8208;cadherin expression was assessed from archived patient tumors by immunohistochemistry, as described earlier for a planned, correlative clinical response analysis.<xref rid="cncr35680-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> The protocol was approved by the institutional review boards at each site, and all patients provided informed consent.</p><fig position="float" fig-type="FIGURE" id="cncr35680-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Expansion&#8208;phase study design. (A)&#160;objectives and major entry criteria of the ovarian and solid&#8208;tumor expansion&#8208;phase cohorts. (B)&#160;Distribution of efficacy&#8208;evaluable patient status in the two cohorts at completion of the study. ECOG indicates Eastern Cooperative Oncology Group; RP2D, recommended phase 2 dose; <sup>90</sup>Y, yttrium&#8208;90.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="CNCR-131-0-g001.jpg"/></fig><p>FF&#8208;21101 was conjugated with <sup>90</sup>YCl<sub>3</sub> for therapeutic treatment by each site, as previously described.<xref rid="cncr35680-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> A <sup>90</sup>Y&#8211;FF&#8208;21101 dose of 25 mCi/m<sup>2</sup> was administered intravenously (without exceeding 60 mCi per administration) every three cycles (one cycle&#160;=&#160;28 days). All doses were infused through a 0.22&#8208;mm inline filter for approximately 10 minutes, not exceeding 1 mL per minute. Patients were monitored for infusion reactions 1 hour after each <sup>90</sup>Y&#8211;FF&#8208;21101 dose.</p><p>Patients were monitored weekly during cycle 1, every 2 weeks during cycle 2, and monthly during each subsequent dosing cycle. Computed tomography or magnetic resonance imaging was conducted for disease assessment at week 8 and every 8 weeks thereafter until documented progressive disease (PD). Patients were treated until they chose to discontinue or experienced PD, unacceptable adverse events (AEs), or any medical condition that prevented further participation. Because P&#8208;cadherin is expressed in the retina, in addition to standard safety monitoring (physical examination, AEs, and clinical laboratory parameters), ophthalmic safety was monitored within 30 days before each <sup>90</sup>Y&#8211;FF&#8208;21101 dose and at the end of treatment.<xref rid="cncr35680-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>
</p></sec><sec id="cncr35680-sec-0040"><title>Patient eligibility</title><p>Trial participants were patients aged 18 years or older who had histologically or cytologically confirmed advanced solid tumors refractory to or relapsed from prior therapy and for whom no alternative therapy was available. The ovarian carcinoma cohort included patients who had confirmed platinum&#8208;refractory/resistant epithelial ovarian, peritoneal, or fallopian tube carcinoma. The solid&#8208;tumor cohort consisted of patients who had the tumors listed above. The complete eligibility requirements are listed in Table&#160;<xref rid="cncr35680-sup-0001" ref-type="supplementary-material">S1</xref>. Briefly, eligible patients had an Eastern Cooperative Oncology Group (ECOG) performance status &#8804;2 and life expectancy &#8805;3 months in the opinion of the investigator, with &#8805;3 weeks elapsed from the last chemotherapy dose (or &#8805;5 half&#8208;lives for targeted agents, including mAbs, whichever was shorter), radiotherapy, major surgery, or experimental treatment; adequate hematologic parameters and renal and hepatic function; and at least one tumor that met target lesion requirements according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST). Because P&#8208;cadherin is expressed in the retina, patients with any history of retinal degenerative disease, retinal vein occlusion, or with any relevant abnormalities identified on ophthalmologic examination were excluded. Patients who had received prior radiation to &gt;30% of the red bone marrow or to the maximal tolerable level for any organ were excluded.</p></sec><sec id="cncr35680-sec-0050"><title>End points</title><p>The primary efficacy end point was the proportion of patients with either a CR or a partial response (PR) according to RECIST<xref rid="cncr35680-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> after <sup>90</sup>Y&#8211;FF&#8208;21101 treatment. The secondary efficacy end points included disease control; the duration of CR, PR, or stable disease (SD) according to RECIST; progression&#8208;free survival (PFS), defined as the time from <sup>90</sup>Y&#8211;FF&#8208;21101 administration to PD or death; and overall survival (OS). Patients were followed for 12 months after the end of treatment for survival. Other secondary end points included FF&#8208;21101 pharmacokinetics (PK) and antidrug&#8211;antibody (ADA) formation to evaluate <sup>90</sup>Y&#8211;FF&#8208;21101 immunogenicity, as previously described.<xref rid="cncr35680-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> PK samples were collected on days 1, 8, and 15 of cycles 1 and 4, and data were analyzed using a noncompartmental approach with Phoenix PK software (Certara). Circulating ADA formation was assessed by measuring serum antihuman/mouse chimeric antibodies on day 1 of cycles 1 (pretreatment), 4, and 5 and at the end of treatment.</p></sec><sec id="cncr35680-sec-0060"><title>Statistical analyses</title><p>Response rates are summarized as the number, percentage, and two&#8208;sided 90% confidence intervals (CIs) for best response (CR, PR, SD, or PD). The Kaplan&#8211;Meier product&#8208;limit method was used to estimate SD duration (date of first SD to date of PD), median PFS, and OS. Patients without PD were censored at the last evaluable disease assessment. Patients who did not experience death were censored at the date the patient was last known to be alive. Statistical analysis software (SAS version 9.4 for Windows or higher; SAS Institute, Inc.) was used for all analyses. Safety end points, PK parameters, and serum antihuman/mouse chimeric antibody concentration&#8211;time profiles were summarized using descriptive statistics.</p></sec></sec><sec id="cncr35680-sec-0070"><title>RESULTS</title><sec id="cncr35680-sec-0080"><title>Patient characteristics</title><p>In total, 57 patients (20 in the ovarian cohort, 37 in the solid&#8208;tumor cohort) were enrolled and treated in the dose&#8208;expansion phase from February 2, 2019, to September 30, 2020 (Table&#160;<xref rid="cncr35680-tbl-0001" ref-type="table">1</xref>). The last patient follow&#8208;up occurred on October 21, 2021. The median age for the ovarian cohort was 66 years (range, 47&#8211;84 years) and included 17 patients with high&#8208;grade serous ovarian carcinoma, two with clear cell carcinoma, one with fallopian carcinoma, and four described as having &#8220;ovarian&#8221; or &#8220;adenocarcinoma&#8221;.&#160;All patients with ovarian carcinoma had received prior platinum therapy and had H&#8208;scores ranging from 0 to 290 (see Table&#160;<xref rid="cncr35680-sup-0002" ref-type="supplementary-material">S2</xref>). The median age for the solid&#8208;tumor cohort was 64 years (range, 36&#8211;89 years), 49% were females, and the cohort included 18 patients with colorectal carcinoma, 12 with pancreatic carcinoma, three with bile duct cancer, and two each with breast and duodenal carcinoma. Patients had various tumor burdens based on target lesion sum of the greatest dimension (19&#8211;228 mm). Patients were heavily pretreated, with a median of five prior therapies in the ovarian cohort and three prior therapies in the solid&#8208;tumor cohort (ranging from one prior therapy for patients with bile duct carcinoma to three prior therapies for those with colorectal carcinoma).</p><table-wrap position="float" id="cncr35680-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Demographics and baseline characteristics in the expansion&#8208;phase cohorts.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1">Ovarian, <italic toggle="yes">n</italic>&#160;=&#160;20</th><th align="left" valign="bottom" rowspan="1" colspan="1">Solid tumor, <italic toggle="yes">n</italic>&#160;=&#160;37</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Age: Median [range], years</td><td align="left" valign="top" rowspan="1" colspan="1">66 [47&#8211;84]</td><td align="left" valign="top" rowspan="1" colspan="1">64 [36&#8211;89]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Male: No. (%)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">19 (51.0)</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">Race: No. (%)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Caucasian</td><td align="left" valign="top" rowspan="1" colspan="1">17 (85.0)</td><td align="left" valign="top" rowspan="1" colspan="1">23 (62.0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Black</td><td align="left" valign="top" rowspan="1" colspan="1">1 (5.0)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (11.0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Asian</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (5.0)</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">ECOG performance status: No. (%)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">10 (50.0)</td><td align="left" valign="top" rowspan="1" colspan="1">11 (30.0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">9 (45.0)</td><td align="left" valign="top" rowspan="1" colspan="1">26 (70.0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">1 (5.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">No. of prior therapies: Median [range]</td><td align="left" valign="top" rowspan="1" colspan="1">5 [1&#8211;9]</td><td align="left" valign="top" rowspan="1" colspan="1">3 [1&#8211;6]</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">PCAD H&#8208;score: Median [range]</td><td align="left" valign="top" rowspan="1" colspan="1">184 [0&#8211;295]</td><td align="left" valign="top" rowspan="1" colspan="1">Colorectal, 207; pancreas, 260</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Tumor type/histology: No. (%)</td><td align="left" valign="top" rowspan="1" colspan="1">Serous, 13 (65.0)</td><td align="left" valign="top" rowspan="1" colspan="1">Colon, 16 (43.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Ovarian or adenocarcinoma, 4 (20.0)</td><td align="left" valign="top" rowspan="1" colspan="1">Pancreas, 12 (32.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Clear cell, 2 (10.0)</td><td align="left" valign="top" rowspan="1" colspan="1">Biliary, 3 (8.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Fallopian tube, 1 (5.0)</td><td align="left" valign="top" rowspan="1" colspan="1">Rectal, 2 (5.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Breast, 2 (5.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Duodenum, 2 (5.0)</td></tr></tbody></table><table-wrap-foot id="cncr35680-ntgp-0001"><fn id="cncr35680-note-0001"><p>Abbreviations: ECOG, Eastern Cooperative Oncology Group; PCAD, P&#8208;cadherin.</p></fn></table-wrap-foot></table-wrap><p>All but two patients were followed for at least 2 months after the first <sup>90</sup>Y&#8211;FF&#8208;21101 dose. Two patients with ovarian carcinoma came off study before the first efficacy evaluation. One patient (baseline ECOG performance status&#160;=&#160;2) withdrew consent on day 7, complaining of fatigue. The other patient (baseline ECOG performance status&#160;=&#160;0) died on day 51 of PD. The median treatment duration was 94 days (range, 7&#8211;322 days) for the ovarian cohort and 57 days (range, 21&#8211;189 days) for the solid&#8208;tumor cohort. Forty&#8208;three patients received one dose of <sup>90</sup>Y&#8211;FF&#8208;21101; and eleven, one, and two patients received two, three, and four doses, respectively. Five of these nine subsequent doses were 20 mCi/m<sup>2</sup>. The median cumulative <sup>90</sup>Y&#8211;FF&#8208;21101 dose was 52.7 mCi (range, 39.9&#8211;211.8 mCi) for the ovarian cohort and 48.3 mCi (range, 35.9&#8211;105.4 mCi) for the solid tumor cohort.</p><p>Patient disposition is detailed in Figure&#160;<xref rid="cncr35680-fig-0001" ref-type="fig">1B</xref> and Table&#160;<xref rid="cncr35680-tbl-0002" ref-type="table">2</xref>. The most common reason for treatment discontinuation was PD, as measured by RECIST or clinical deterioration (40 patients [70%], including patients who died before withdrawing from treatment). The remaining reasons were AEs in nine patients (16%), including two fatal, possibly related AEs and seven AEs unrelated to FF&#8208;21101; withdrawal of consent in six patients (11%), and physician decision in one patient (2%).</p><table-wrap position="float" id="cncr35680-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Patient disposition in the expansion&#8208;phase cohorts.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr><th align="left" valign="bottom" rowspan="1" colspan="1"/><th colspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1">No. (%)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1">Ovarian, <italic toggle="yes">n</italic>&#160;=&#160;20</th><th align="left" valign="bottom" rowspan="1" colspan="1">Solid tumor, <italic toggle="yes">n</italic>&#160;=&#160;37</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Signed informed consent</td><td align="left" valign="top" rowspan="1" colspan="1">22</td><td align="left" valign="top" rowspan="1" colspan="1">41</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Screen failures</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Enrolled and treated</td><td align="left" valign="top" rowspan="1" colspan="1">20</td><td align="left" valign="top" rowspan="1" colspan="1">37</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">Treatment discontinuation</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Progressive disease</td><td align="left" valign="top" rowspan="1" colspan="1">15(75.0)</td><td align="left" valign="top" rowspan="1" colspan="1">25 (68.0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Adverse event related to FF&#8208;21101<xref rid="cncr35680-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">1 (5.0)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (3.0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Adverse event unrelated to FF&#8208;21101</td><td align="left" valign="top" rowspan="1" colspan="1">2 (10.0)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (14.0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Withdrawal of consent</td><td align="left" valign="top" rowspan="1" colspan="1">1 (5.0)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (16.0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Physician decision</td><td align="left" valign="top" rowspan="1" colspan="1">1 (5.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr></tbody></table><table-wrap-foot id="cncr35680-ntgp-0002"><fn id="cncr35680-note-0002"><label>
<sup>a</sup>
</label><p>One patient had ovarian cancer with veno&#8208;occlusive disease, and one patient had pancreatic cancer with intracranial hemorrhage.</p></fn></table-wrap-foot></table-wrap></sec><sec id="cncr35680-sec-0090"><title>Pharmacokinetics</title><p>The PK results were consistent with those observed in the dose&#8208;escalation phase (see Table&#160;<xref rid="cncr35680-sup-0003" ref-type="supplementary-material">S3</xref>).<xref rid="cncr35680-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> At the recommended phase 2 dose (25 mCi/m<sup>2</sup>), the mean half&#8208;life was 62.9&#160;&#177;&#160;14.2 hours, and the area under the curve was 145,000&#160;&#177;&#160;37,600 hours per&#8729;ng/mL. The mean clearance was 22.7&#160;&#177;&#160;5.9 mL per hour/m<sup>2</sup> (range, 11.9&#8211;36.9 mL per hour/m<sup>2</sup>). The mean apparent volume of distribution was 2000&#160;&#177;&#160;445 mL<sup>2</sup> (range, 1140&#8211;3070 mL/m<sup>2</sup>). Systemic <sup>90</sup>Y&#8211;FF&#8208;21101 exposure, defined by the mean maximum serum concentration and area under the curve 0&#8211;t), was similar between cycle 1 and cycle 4.</p></sec><sec id="cncr35680-sec-0100"><title>Efficacy</title><p>Of the 20 patients in the ovarian cohort, 18 were response evaluable by RECIST, and no patients had a CR or PR. A best response of SD was reported for 12 patients (66%), and PD was the best response reported for six patients (33%). One patient had an 18% decrease in the sum of target lesions (from 22 to 18 mm) in their first evaluation but met the PD criteria 8 weeks later, developing a new peritoneal nodule. In the solid&#8208;tumor cohort, a best response of SD was reported for nine patients (29%), and PD was the best response reported for 22 patients (71%). The median SD duration was 169 days (90% CI, 62&#8211;268 days; <italic toggle="yes">n</italic>&#160;=&#160;12, with six censored) in the ovarian cohort and 66 days (90% CI, 56&#8211;110 days; <italic toggle="yes">n</italic>&#160;=&#160;9, with five censored) in the solid&#8208;tumor cohort.</p><p>PFS and OS were calculated for both cohorts (Figure&#160;<xref rid="cncr35680-fig-0002" ref-type="fig">2A,B</xref>). The median PFS was 118 days (90% CI, 54&#8211;222 days) for the ovarian cohort and 55 days (90% CI, 54&#8211;857 days) for the solid&#8208;tumor cohort. The median PFS for specific tumor types within the solid&#8208;tumor cohort were similar to the cohort median: 56 days (90% CI, 52&#8211;84 days) for patients with colorectal and duodenal cancer and 55 days (90% CI, 48&#8211;56 days) for those with pancreatic adenocarcinoma. The median OS was 244 days (90% CI, 215&#8211;435 days) for the ovarian cohort and 198 days (90% CI, 142&#8211;235 days) for the solid&#8208;tumor cohort. These results are consistent with reported durations for late&#8208;stage patients with each cancer type. Cancer antigen 125 progression (a confirmed doubling [or two&#8208;fold increase] or more) was observed in four patients with ovarian carcinoma on study. A cancer antigen 125 progression or response could not be determined in the other 16 patients.</p><fig position="float" fig-type="FIGURE" id="cncr35680-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Progression&#8208;free and overall survival in the ovarian (<italic toggle="yes">n</italic>&#160;=&#160;20) and solid&#8208;tumor (<italic toggle="yes">n</italic>&#160;=&#160;37) expansion&#8208;phase cohorts. (A)&#160;Progression&#8208;free survival (in days) was defined as the length of time from the date of the first <sup>90</sup>Y&#8211;FF&#8208;21101 dose to the date of the first objective evidence of progressive disease or death (date of first progressive disease or death&#160;&#8722;&#160;date of first <sup>90</sup>Y&#8211;FF&#8208;21101 dose&#160;+&#160;1). For patients with neither progressive disease nor death, progression&#8208;free survival was censored at the date of the last disease&#8208;evaluable assessment. (B)&#160;Overall survival (in days) was defined as the length of time from the date of the first <sup>90</sup>Y&#8211;FF&#8208;21101 dose to the date of death from any cause (date of death&#160;&#8722;&#160;date of first <sup>90</sup>Y&#8211;FF&#8208;21101 dose&#160;+&#160;1). In surviving patients, overall survival was censored at the date the patient was last known to be alive or the date of last contact. Q 3 months indicates every 3 months; IV, intravenous; <sup>90</sup>Y, yttrium&#8208;90.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="CNCR-131-0-g002.jpg"/></fig><sec id="cncr35680-sec-0110"><title>Target expression analysis</title><p>H&#8208;scores ranged from 0 to 295, with median scores of 180 in ovarian cancer, 207 in colorectal cancer, and 260 in pancreatic adenocarcinoma. No clear correlation was observed between H&#8208;scores and time on study. However, all patients with longer term disease control (&gt;20 weeks) had P&#8208;cadherin H&#8208;scores &#8805;150, including two patients with colon cancer of 16 with H&#8208;scores &#8805;150 and five patients with ovarian cancer of 13 with H&#8208;scores &#8805;150 (see Figure&#160;<xref rid="cncr35680-sup-0001" ref-type="supplementary-material">S1A&#8211;E</xref>).</p></sec></sec><sec id="cncr35680-sec-0120"><title>Safety</title><p>All patients experienced AEs, and all but one patient in each cohort experienced a suspected treatment&#8208;related AE. Of the 10 most common AEs, five were hematologic. Table&#160;<xref rid="cncr35680-tbl-0003" ref-type="table">3</xref> lists the most common treatment&#8208;emergent AEs in occurred in two or more patients and all treatment&#8208;related AEs.</p><table-wrap position="float" id="cncr35680-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>Treatment&#8208;emergent adverse events occurring in more than two patients in the ovarian and solid&#8208;tumor expansion&#8208;phase cohorts.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr><th align="left" valign="bottom" rowspan="1" colspan="1"/><th colspan="4" style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1">No. (%)</th></tr><tr><th align="left" valign="bottom" rowspan="1" colspan="1"/><th colspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1">All AEs in all patients, <italic toggle="yes">n&#160;=&#160;57</italic>
</th><th colspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1">Treatment&#8208;related AEs in all patients, <italic toggle="yes">n&#160;=&#160;57</italic>
<xref rid="cncr35680-note-0004" ref-type="table-fn">
<sup>a</sup>
</xref>
</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Preferred term</th><th align="left" valign="bottom" rowspan="1" colspan="1">All grades</th><th align="left" valign="bottom" rowspan="1" colspan="1">Grade &#8805;3</th><th align="left" valign="bottom" rowspan="1" colspan="1">All grades</th><th align="left" valign="bottom" rowspan="1" colspan="1">Grade &#8805;3</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Thrombocytopenia</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">41 (72.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">23 (40.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">40 (70.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">22 (39.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fatigue</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">38 (67.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3 (5.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">35 (61.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">2 (4.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lymphopenia</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">36 (63.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">31 (54.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">35 (61.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">31 (54.0.)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anemia</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">29 (51.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">8 (14.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">27 (47.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">6 (11.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Decreased appetite</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">27 (47.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">20 (35.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1 (2.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Nausea</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">25 (44.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">22 (39.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">2 (4.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Leukopenia</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">20 (35.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">9 (16.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">20 (35.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">9 (16.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Abdominal pain</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">18 (32.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3 (5.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Vomiting</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">18 (32.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">11 (19.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Blood albumin decreased</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">17 (30.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3 (5.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">6 (11.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Blood sodium decreased</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">15 (26.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">4 (7.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Dysgeusia</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">15 (26.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">15 (26.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Neutropenia</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">15 (26.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">6 (11.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">15 (26.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">6 (11)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Blood alkaline phosphatase increased</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">14 (25.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">5 (9.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1 (2.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Blood calcium decreased</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">14 (25.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3 (5.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">4 (7.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1 (2.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Blood phosphorus decreased</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">14 (25.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">6 (11.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AST increased</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">13 (23.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">6 (11.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">2 (4.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Blood bilirubin increased</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">12 (21.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">6 (11.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">6 (11.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3 (5.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diarrhea</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">12 (21.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">8 (14.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Dyspnea</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">12 (21.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">5 (9.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">4 (7.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Blood potassium decreased</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">11 (19.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">2 (4.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Blood glucose increased</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">10 (18.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Blood magnesium decreased</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">10 (18.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3 (5.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Constipation</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">10 (18.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3 (5.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Blood lactate dehydrogenase increased</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">9 (16.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">2 (4.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cough</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">7 (12.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1 (2.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Back pain</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">6 (11.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1 (2.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Blood creatinine increased</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">6 (11.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1 (2.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ALT increased</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">5 (9.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">2 (4.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Blood bicarbonate decreased</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">5 (9.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Dehydration</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">5 (9.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1 (2.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Headache</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">5 (9.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1 (2.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Blood glucose decreased</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">4 (7.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Dizziness</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">4 (7.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">4 (7.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Epistaxis</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">4 (7.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3 (5.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fall</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">4 (7.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Oral candidiasis</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">4 (7.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pyrexia</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">4 (7.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Stomatitis</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">4 (7.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">4 (7.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Dyspepsia</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3 (5.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3 (5.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hot flush</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3 (5.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">2 (4.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mucosal inflammation</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3 (5.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3 (5.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Edema, peripheral</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3 (5.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pain</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3 (5.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pain in extremity</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3 (5.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sepsis</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3 (5.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">*Weight decreased</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3 (5.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">2 (4.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr></tbody></table><table-wrap-foot id="cncr35680-ntgp-0003"><fn id="cncr35680-note-0003"><p>Abbreviations: AEs, adverse events; AST, aspartate aminotransferase; ALT, alanine aminotransferase.</p></fn><fn id="cncr35680-note-0004"><label>
<sup>a</sup>
</label><p>Among treatment&#8208;emergent AEs occurring in more than two patients, the number of patients with AEs suspected to be related to treatment with the study drug (FF&#8208;21101).</p></fn></table-wrap-foot></table-wrap><p>Persistent grade &#8805;3 thrombocytopenia was present in three patients, all of whom had received multiple prior regimens of carboplatin/paclitaxel or other cytotoxic agents. These findings were clinically distinct from the transient thrombocytopenia observed in the dose&#8208;escalation phase. Therefore, restrictions were placed on repeated dose administration for patients who experienced severe or persistent thrombocytopenia after <sup>90</sup>Y&#8211;FF&#8208;21101 administration. Specifically, patients who developed grade 4 thrombocytopenia (&lt;25,000/&#181;L) or who developed grade 3 thrombocytopenia (&lt;50,000/&#181;L) more than 56 days after a <sup>90</sup>Y&#8211;FF&#8208;21101 infusion could not receive further <sup>90</sup>Y&#8211;FF&#8208;21101 treatment. Day 15 platelet counts were added for all cycles beginning with cycle 3.</p><p>Five patients required dose reductions to 20 mCi/m<sup>2</sup>. Four patients had fatal AEs while actively on study. Two patients had fatal AEs that may have been caused, at least in part, by <sup>90</sup>Y&#8211;FF&#8208;21101. A patient aged 56 years with ovarian carcinoma who suffered from morbid obesity, hypertension, and upper extremity superficial thrombosis developed portal vein thrombosis and hyperbilirubinemia after approximately 7 months on study and receiving three <sup>90</sup>Y&#8211;FF&#8208;21101 doses. Her prior therapy included multiple lines of cytotoxic therapy and maytansinoid antibody&#8211;drug conjugate therapy. A liver biopsy confirmed sinusoidal obstruction syndrome (veno&#8208;occlusive disease). Despite treatment with defibrotide, the patient became hypotensive and increasingly oxygen&#8208;dependent, ultimately dying on comfort care measures. A second patient with pancreatic cancer died of intracranial hemorrhage in a previously unknown cerebral metastases. This event occurred in the setting of grade 3 thrombocytopenia (74,000/&#181;L) and likely was caused by <sup>90</sup>Y&#8211;FF&#8208;21101, which may have contributed to cerebral bleeding. Two additional deaths occurred: one in a patient who developed fatal dyspnea/pneumonia and one in a patient who experienced acute respiratory failure while in sepsis. These deaths were considered to be caused by the underlying malignancies. A fifth patient died of PD, which manifested as vaginal bleeding because of tumor encroachment on a uterine artery.</p><p>AEs that met the regulatory definition of being serious AEs (SAEs) occurred in seven patients in the ovarian cohort and 19 patients in the solid&#8208;tumor cohort. Six SAEs in the ovarian cohort were considered possibly related to <sup>90</sup>Y&#8211;FF&#8208;21101, including grade 3 incidences of anorexia, nausea, fatigue, and thrombocytopenia; grade 4 myelodysplastic syndrome; and grade 5 sinusoidal obstruction syndrome. The only suspected treatment&#8208;related SAE in the solid&#8208;tumor cohort was the intracranial hemorrhage.</p><sec id="cncr35680-sec-0130"><title>Evaluation of antidrug antibody formation</title><p>Specific, treatment&#8208;emergent ADA responses were detected in 11 patients but did not appear to alter <sup>90</sup>Y&#8211;FF&#8208;21101 clearance. Whether the ADA is neutralizing remains unknown. Two patients who received multiple <sup>90</sup>Y&#8211;FF&#8208;21101 doses and had persistent ADA responses throughout the course of therapy maintained SD for 6 and 12 months.</p></sec></sec></sec><sec id="cncr35680-sec-0140"><title>DISCUSSION</title><p>To our knowledge, this is the fourth clinical trial of a P&#8208;cadherin&#8211;directed therapy. Each successive clinical trial has tested a different investigational therapy, reflecting technological advances in drug development. The first trial used PF03732010, an unmodified mAb targeting P&#8208;cadherin; despite promising preclinical data, a lack of clinical activity stopped PF03732010 development.<xref rid="cncr35680-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> More recently, Harding et&#160;al. reported on PF&#8208;06671008, a modified, bispecific, T&#8208;cell engager.<xref rid="cncr35680-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> However, no patient in their study had a radiologic response, and cytokine release syndrome was a prominent toxicity.<xref rid="cncr35680-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> Duca et&#160;al. reported on PCA062, an antibody&#8211;drug combination targeting P&#8208;cadherin to deliver maytansinoid.<xref rid="cncr35680-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> Of 47 treated patients in that study, only one patient with head and neck cancer had a PR,<xref rid="cncr35680-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> and the safety profile of PCA062 was consistent with known toxicities associated with maytansin. Development was stopped for both PCA062 and PF&#8208;06671008.</p><p>We stopped enrollment in our trial because none of the 18 evaluable patients in the ovarian cohort had a treatment response. In the solid&#8208;tumor cohort, we planned to enroll patients with high P&#8208;cadherin&#8211;expressing tumors, emphasizing patients with colorectal, pancreatic, and biliary adenocarcinomas. Enrollment occurred concurrently for both cohorts and stopped simultaneously.</p><p>Although we did not meet predefined efficacy criteria, we believe the results of this trial are useful for further development of treatments targeting P&#8208;cadherin&#8211;expressing solid tumors.</p><p>It is well established that the principal side effect of <sup>90</sup>Y is hematopoietic suppression.<xref rid="cncr35680-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="cncr35680-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> Like all &#946; emitters, the mechanism of action is DNA damage through high&#8208;energy linear transfer, to which bone marrow stem cells are particularly sensitive.<xref rid="cncr35680-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> In various studies using <sup>90</sup>Y mAb therapeutics at doses ranging from approximately 3 to 50 mCi/m<sup>2</sup>, the incidence of grade &#8805;3 thrombocytopenia and neutropenia could be as high as 75%.<xref rid="cncr35680-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="cncr35680-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="cncr35680-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="cncr35680-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> When multiple doses were given over time, the incidence of thrombocytopenia and neutropenia increased over time as well.<xref rid="cncr35680-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> Patients generally recover, but the extent of prior chemotherapy is associated with prolonged or diminished recovery.<xref rid="cncr35680-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> The incidence of hematologic side effects reported here and in the dose&#8208;finding part of the trial were consistent with these reported studies. Apart from a possible case of sinusoidal obstruction syndrome, there were no AEs suggestive of radiation damage to other organs, consistent with the <sup>111</sup>In dosimetric measurements.<xref rid="cncr35680-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> No safety findings were specifically attributable to P&#8208;cadherin targeting in our study; and, despite the retinal expression of P&#8208;cadherin, no visual toxicities were observed.</p><p>Four SAEs resulting in death were reported, including two that were considered possibly treatment&#8208;related: thrombocytopenia may have contributed to intracranial hemorrhage; and, although unexpected, veno&#8208;occlusive disease has been associated rarely with radiotherapy and past treatments using antibody&#8211;drug conjugates or cytotoxic agents. Hepatic sinusoidal obstruction syndrome shares many features with radiation&#8208;induced liver injury caused by <sup>90</sup>Y sphere ablation, as described by Sangro et&#160;al.<xref rid="cncr35680-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> and reviewed by Kim and Jung.<xref rid="cncr35680-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> Hepatic injury is typically reported several weeks after the delivery of radiation doses &gt;30 Gy, and patients with prior chemotherapy experience an elevated risk of hepatic injury. An enhanced risk of sinusoidal obstruction has also been reported in patients treated with gemtuzumab ozogamicin.<xref rid="cncr35680-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> In our study, the patient who experienced veno&#8208;occlusive liver disease had received three therapies associated with developing sinusoidal obstruction syndrome: cytotoxic therapy, antibody&#8211;drug conjugates, and <sup>90</sup>Y radiation carried by FF&#8208;21101. Dosimetry experiments indicate that our dosing regimen exposed the liver to a radiation dose much lower than 30 Gy. Therefore, we believe that sinusoidal obstruction syndrome was unlikely to be caused by the radiation dose alone.</p><p>Increasingly sophisticated RPT agents have led to recent successes, as comprehensively reviewed in several valuable articles.<xref rid="cncr35680-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="cncr35680-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> However, RPT for solid tumors remains challenging, perhaps because solid tumors require higher radiation doses than hematologic malignancies.<xref rid="cncr35680-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="cncr35680-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> Other RPTs have been unsuccessful in treating ovarian carcinomas and various gastrointestinal tumors.<xref rid="cncr35680-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>, <xref rid="cncr35680-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> The PFS and OS rates observed for the ovarian cohort in our trial were consistent with those reported for heavily pretreated patients in retrospective analyses and for patients with advanced disease in prospective trials.<xref rid="cncr35680-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>
</p><p>P&#8208;cadherin is overexpressed in many malignancies, with little expression in normal tissues other than the eye. Clinical trials testing various approaches targeting tumor&#8208;associated antigens that are similarly overexpressed in solid tumors, including carcinoembryonic antigen and mucin 1, have also been unsuccessful.<xref rid="cncr35680-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>, <xref rid="cncr35680-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>, <xref rid="cncr35680-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>, <xref rid="cncr35680-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> Overexpressed antigens may protect them from therapies that otherwise would work against exposed tumor cells. The extensive extracellular matrix in many solid tumors may explain why the radiation dose necessary for antitumor effects is greater than the dose required for hematologic tumors.<xref rid="cncr35680-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> The addition of an &#945; emitter, such as radium&#8208;223 or actinium&#8208;225, to FF&#8208;21101 or similar carriers could increase extracellular matrix penetration and improve effectiveness against solid tumors. In addition, solid tumors have hypoxic cores that diminish &#946;&#8208;emitter efficacy but are unlikely to affect &#945;&#8208;emitter activity.<xref rid="cncr35680-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="cncr35680-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>
</p><p>In pursuit of this approach, it has been demonstrated that actinium&#8208;225 can be conjugated to FF&#8208;21101, and preliminary preclinical results show promise.<xref rid="cncr35680-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> Although this <sup>90</sup>Y&#8211;FF&#8208;21101 trial and other P&#8208;cadherin&#8211;targeting trials have been unsuccessful, P&#8208;cadherin remains an attractive and important target, and valuable lessons have been learned. Further investigation may achieve the therapeutic potential of P&#8208;cadherin&#8211;directed RPT.</p></sec><sec id="cncr35680-sec-0150"><title>AUTHOR CONTRIBUTIONS</title><p>
<bold>Devalingam Mahalingam</bold>: Writing&#8211;original draft; writing&#8211;review and editing; investigation. <bold>Taofeek K. Owonikoko</bold>: Investigation. <bold>Ebrahim Delpassand</bold>: Investigation. <bold>Mary F. Mulcahy</bold>: Investigation. <bold>Aparna Kalyan</bold>: Investigation. <bold>Susanna Ulahannan</bold>: Investigation. <bold>Kin Cheung</bold>: Formal analysis; software; data curation; validation; investigation. <bold>Yasayuki Izumi</bold>: Investigation. <bold>Mary Johansen</bold>: Writing&#8211;original draft; writing&#8211;review and editing; data curation; validation. <bold>Timothy Madden</bold>: Writing&#8211;original draft; writing&#8211;review and editing; investigation; validation; data curation. <bold>Susumu Shimoyam</bold>a: Investigation; supervision; conceptualization; funding acquisition. <bold>Ruth Ann Subach</bold>: Conceptualization; investigation; funding acquisition; supervision; data curation; validation. <bold>Takeaki Suzuki</bold>: Conceptualization; investigation; funding acquisition; supervision. <bold>David S. Wages</bold>: Writing&#8211;original draft; writing&#8211;review and editing; investigation. <bold>Catherine Wheeler</bold>: Conceptualization; investigation; funding acquisition; supervision. <bold>Debra L. Richardson</bold>: Investigation.</p></sec><sec sec-type="COI-statement" id="cncr35680-sec-0170"><title>CONFLICT OF INTEREST STATEMENT</title><p>Devalingam Mahalingam reports grants/contracts from Actuate Therapeutics, ADC Therapeutics, Amgen, AVEO, Bayer, Blueprint Medicines, BMS, BioNTech, Dialectic Therapeutics, Epizyme, FUJIFILM Pharmaceuticals USA, ImmuneSensor, Immune&#8208;Onc Therapeutics, Leap Therapeutics, Lycera Corp, Merck, Millennium, MiNA Alpha, NGM Biopharmaceuticals, Novartis, Oncolytics, Orano Med, Puma, Qurient, Repare Therapeutics, Triumvira Immunologics, Vigeo Therapeutics, Warewolf Therapeutics; and personal/consulting fees from Actuate, Amgen, Bristol Myers Squibb, Eisai, Exelexis, Qurient&#160;and OncoOne outside the submitted work. Taofeek K. Owonikoko reports grants/contracts from Eli Lilly and Company and Novartis; personal/consulting fees from Amgen Inc., AstraZeneca, Bayer, Cambium Oncology, Coherus Biosciences Inc., Daiichi Sankyo Company, Exelixis Inc., Janssen Biotech Inc., Jazz Pharmaceuticals Inc., Merck, Meryx, and Puma Biotechnology Inc.; service on an advisory board or review/data safety monitoring committee at Genentech and Takeda Oncology; and stock ownership in Coherus Biosciences Inc. and GenCart outside the submitted work. Aparna Kalyan reports personal/consulting fees from AstraZeneca, AstraZeneca UK Limited, and Exelixis Inc.; and support for other professional activities from AstraZeneca and Genentech outside the submitted work. Susanna Ulahannan reports grants/contracts from AbbVie, Adlai Nortye, Arcus, ArQule Inc., Array Biopharma Inc., AstraZeneca, Atreca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Ciclomed LLC, Eisai, Erasca, Evelo Biosciences Inc., Exelexis, G1 Therapeutics Inc., GlaxoSmithKline, Hutch Med, IGM Biosciences, Incyte Corporation, Isofol, Klus Pharma Inc., Macrogenics, Merck, Mersana Company Inc., OncoMed Pharmaceutical, Pfizer Canada Inc., Pfizer Inc., Purple Bioteach, Regeneron Inc., Revolution Medicines Inc., Synermore Biologics Company, Syros, Takeda Oncology, Tarveda Therapeutics, Tempest, Tesaro Inc., Tizona, and Vigeo Therapeutics Inc.; and personal/consulting fees from AstraZeneca, Eisai, and IGM Biosciences outside the submitted work. Debra L. Richardson reports personal/consulting fees from AstraZeneca, Genmab, GlaxoSmithKline, Immunogen, Incyte, Mersana, and Repare Therapeutics; and support for other professional activities from Mentalis Pharmaceuticals outside the submitted work. The remaining authors disclosed no conflicts of interest.</p><p>Kin Cheung, Mary Johansen, Timothy Madden, Susumu Shimoyama, David S. Wages, and Catherine Wheeler are contractors for, or employees of, FUJIFILM Pharmaceuticals USA Inc</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="cncr35680-sup-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>Supplementary Material</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CNCR-131-0-s002.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="cncr35680-sup-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>Supplementary Material</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CNCR-131-0-s009.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="cncr35680-sup-0003" position="float" content-type="local-data" orientation="portrait"><caption><p>Supplementary Material</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CNCR-131-0-s006.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="cncr35680-sup-0004" position="float" content-type="local-data" orientation="portrait"><caption><p>Supplementary Material</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CNCR-131-0-s004.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="cncr35680-sup-0005" position="float" content-type="local-data" orientation="portrait"><caption><p>Supplementary Material</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CNCR-131-0-s008.tif" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="cncr35680-sup-0006" position="float" content-type="local-data" orientation="portrait"><caption><p>Supplementary Material</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CNCR-131-0-s007.tif" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="cncr35680-sup-0007" position="float" content-type="local-data" orientation="portrait"><caption><p>Supplementary Material</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CNCR-131-0-s003.tif" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="cncr35680-sup-0008" position="float" content-type="local-data" orientation="portrait"><caption><p>Supplementary Material</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CNCR-131-0-s001.tif" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="cncr35680-sup-0009" position="float" content-type="local-data" orientation="portrait"><caption><p>Supplementary Material</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CNCR-131-0-s005.tif" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="cncr35680-sec-0160"><title>ACKNOWLEDGMENTS</title><p>This study was funded by FUJIFILM Pharmaceuticals USA. We thank the patients and their families for their participation in the trial. We also thank Julie Edwards at BioScience Writers, LLC, for preparation of the article.</p></ack><sec sec-type="data-availability" id="cncr35680-sec-0190"><title>DATA AVAILABILITY STATEMENT</title><p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></sec><ref-list content-type="cited-references" id="cncr35680-bibl-0001"><title>REFERENCES</title><ref id="cncr35680-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="cncr35680-cit-0001"><string-name name-style="western"><surname>Sgouros</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Bodei</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>McDevitt</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Nedrow</surname><given-names>JR</given-names></string-name>. <article-title>Radiopharmaceutical therapy in cancer: clinical advances and challenges</article-title>. <source>Nat Rev Drug Discov</source>. <year>2020</year>;<volume>19</volume>(<issue>9</issue>):<fpage>589</fpage>&#8208;<lpage>608</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41573-020-0073-9</pub-id><pub-id pub-id-type="pmid">32728208</pub-id><pub-id pub-id-type="pmcid">PMC7390460</pub-id></mixed-citation></ref><ref id="cncr35680-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="cncr35680-cit-0002"><string-name name-style="western"><surname>Lepareur</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Ram&#233;e</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Mougin&#8208;Degraef</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bourgeois</surname><given-names>M</given-names></string-name>. <article-title>Clinical advances and perspectives in targeted radionuclide therapy</article-title>. <source>Pharmaceutics</source>. <year>2023</year>;<volume>15</volume>(<issue>6</issue>):<elocation-id>1733</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/pharmaceutics15061733</pub-id><pub-id pub-id-type="pmid">37376181</pub-id><pub-id pub-id-type="pmcid">PMC10303056</pub-id></mixed-citation></ref><ref id="cncr35680-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="cncr35680-cit-0003"><string-name name-style="western"><surname>White</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Escorcia</surname><given-names>FE</given-names></string-name>, <string-name name-style="western"><surname>Viola</surname><given-names>NT</given-names></string-name>. <article-title>Perspectives on metals&#8208;based radioimmunotherapy (RIT): moving forward</article-title>. <source>Theranostics</source>. <year>2021</year>;<volume>11</volume>(<issue>13</issue>):<fpage>6293</fpage>&#8208;<lpage>6314</lpage>. doi:<pub-id pub-id-type="doi">10.7150/thno.57177</pub-id><pub-id pub-id-type="pmid">33995659</pub-id><pub-id pub-id-type="pmcid">PMC8120204</pub-id></mixed-citation></ref><ref id="cncr35680-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="cncr35680-cit-0004"><string-name name-style="western"><surname>Zinn</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Vazquez&#8208;Lombardi</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Zimmermann</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Sapra</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Jermutus</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Christ</surname><given-names>D</given-names></string-name>. <article-title>Advances in antibody&#8208;based therapy in oncology</article-title>. <source>Nat Cancer</source>. <year>2023</year>;<volume>4</volume>(<issue>2</issue>):<fpage>165</fpage>&#8208;<lpage>180</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s43018-023-00516-z</pub-id><pub-id pub-id-type="pmid">36806801</pub-id></mixed-citation></ref><ref id="cncr35680-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="cncr35680-cit-0005"><string-name name-style="western"><surname>Kraeber&#8208;Bod&#233;r&#233;</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Barbet</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Chatal</surname><given-names>JF</given-names></string-name>. <article-title>Radioimmunotherapy: from current clinical success to future industrial breakthrough?</article-title><source>J Nucl Med</source>. <year>2016</year>;<volume>57</volume>(<issue>3</issue>):<fpage>329</fpage>&#8208;<lpage>331</lpage>. doi:<pub-id pub-id-type="doi">10.2967/jnumed.115.167247</pub-id><pub-id pub-id-type="pmid">26514174</pub-id></mixed-citation></ref><ref id="cncr35680-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="cncr35680-cit-0006"><string-name name-style="western"><surname>Goldenberg</surname><given-names>DM</given-names></string-name>. <article-title>Radiolabelled monoclonal antibodies in the treatment of metastatic cancer</article-title>. <source>Curr Oncol</source>. <year>2007</year>;<volume>14</volume>(<issue>1</issue>):<fpage>39</fpage>&#8208;<lpage>42</lpage>. doi:<pub-id pub-id-type="doi">10.3747/co.2007.112</pub-id><pub-id pub-id-type="pmid">17576463</pub-id><pub-id pub-id-type="pmcid">PMC1891189</pub-id></mixed-citation></ref><ref id="cncr35680-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="cncr35680-cit-0007"><string-name name-style="western"><surname>Yu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>. <article-title>Cadherin signaling in cancer: its functions and role as a therapeutic target</article-title>. <source>Front Oncol</source>. <year>2019</year>;<volume>9</volume>:<elocation-id>989</elocation-id>. doi:<pub-id pub-id-type="doi">10.3389/fonc.2019.00989</pub-id><pub-id pub-id-type="pmid">31637214</pub-id><pub-id pub-id-type="pmcid">PMC6788064</pub-id></mixed-citation></ref><ref id="cncr35680-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="cncr35680-cit-0008"><string-name name-style="western"><surname>Paredes</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Figueiredo</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Albergaria</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Epithelial E&#8208; and P&#8208;cadherins: role and clinical significance in cancer</article-title>. <source>Biochim Biophys Acta</source>. <year>2012</year>;<volume>1826</volume>(<issue>2</issue>):<fpage>297</fpage>&#8208;<lpage>311</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bbcan.2012.05.002</pub-id><pub-id pub-id-type="pmid">22613680</pub-id></mixed-citation></ref><ref id="cncr35680-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="cncr35680-cit-0009"><string-name name-style="western"><surname>Subbiah</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Erwin</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Mawlawi</surname><given-names>O</given-names></string-name>, et&#160;al. <article-title>Phase I study of P&#8208;cadherin&#8211;targeted radioimmunotherapy with (90)Y&#8211;FF&#8208;21101 monoclonal antibody in solid tumors</article-title>. <source>Clin Cancer Res</source>. <year>2020</year>;<volume>26</volume>(<issue>22</issue>):<fpage>5830</fpage>&#8208;<lpage>5842</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.Ccr-20-0037</pub-id><pub-id pub-id-type="pmid">32816889</pub-id></mixed-citation></ref><ref id="cncr35680-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="cncr35680-cit-0010"><string-name name-style="western"><surname>Duca</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lim</surname><given-names>DW</given-names></string-name>, <string-name name-style="western"><surname>Subbiah</surname><given-names>V</given-names></string-name>, et&#160;al. <article-title>A first&#8208;in&#8208;human, phase I, multicenter, open&#8208;label, dose&#8208;escalation study of PCA062: an antibody&#8208;drug conjugate targeting P&#8208;cadherin, in patients with solid tumors</article-title>. <source>Mol Cancer Ther</source>. <year>2022</year>;<volume>21</volume>(<issue>4</issue>):<fpage>625</fpage>&#8208;<lpage>634</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1535-7163.Mct-21-0652</pub-id><pub-id pub-id-type="pmid">35131875</pub-id></mixed-citation></ref><ref id="cncr35680-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="cncr35680-cit-0011"><string-name name-style="western"><surname>Harding</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Garrido&#8208;Laguna</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>X</given-names></string-name>, et&#160;al. <article-title>A phase 1 dose&#8208;escalation study of PF&#8208;06671008, a bispecific T&#8208;cell&#8211;engaging therapy targeting P&#8208;cadherin in patients with advanced solid tumors</article-title>. <source>Front Immunol</source>. <year>2022</year>;<volume>13</volume>:<elocation-id>845417</elocation-id>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2022.845417</pub-id><pub-id pub-id-type="pmid">35493516</pub-id><pub-id pub-id-type="pmcid">PMC9047766</pub-id></mixed-citation></ref><ref id="cncr35680-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="cncr35680-cit-0012"><string-name name-style="western"><surname>Rieger</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>De Filippi</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Lind&#233;n</surname><given-names>O</given-names></string-name>, et&#160;al. <article-title>90&#8208;yttrium&#8208;ibritumomab tiuxetan as first&#8208;line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow&#8208;up of 9.6 years</article-title>. <source>Ann Hematol</source>. <year>2022</year>;<volume>101</volume>(<issue>4</issue>):<fpage>781</fpage>&#8208;<lpage>788</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00277-022-04781-3</pub-id><pub-id pub-id-type="pmid">35150296</pub-id><pub-id pub-id-type="pmcid">PMC8913448</pub-id></mixed-citation></ref><ref id="cncr35680-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="cncr35680-cit-0013"><string-name name-style="western"><surname>Funase</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Nakamura</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Kajita</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Preclinical characterization of the radioimmunoconjugate (111)In or (90)Y&#8211;FF&#8208;21101 against a P&#8208;cadherin&#8211;expressing tumor in a mouse xenograft model and a nonhuman primate</article-title>. <source>J Nucl Med</source>. <year>2021</year>;<volume>62</volume>(<issue>2</issue>):<fpage>232</fpage>&#8208;<lpage>239</lpage>. doi:<pub-id pub-id-type="doi">10.2967/jnumed.120.245837</pub-id><pub-id pub-id-type="pmid">32737245</pub-id><pub-id pub-id-type="pmcid">PMC8679590</pub-id></mixed-citation></ref><ref id="cncr35680-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="cncr35680-cit-0014"><string-name name-style="western"><surname>Richman</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>DeNardo</surname><given-names>SJ</given-names></string-name>. <article-title>Systemic radiotherapy in metastatic breast cancer using 90Y&#8208;linked monoclonal MUC&#8208;1 antibodies</article-title>. <source>Crit Rev Oncol Hematol</source>. <year>2001</year>;<volume>38</volume>(<issue>1</issue>):<fpage>25</fpage>&#8208;<lpage>35</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s1040-8428(00)00136-0</pub-id><pub-id pub-id-type="pmid">11255079</pub-id></mixed-citation></ref><ref id="cncr35680-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="cncr35680-cit-0015"><string-name name-style="western"><surname>Imai</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Hirata</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Irie</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Identification of a novel tumor&#8208;associated antigen, cadherin 3/P&#8208;cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers</article-title>. <source>Clin Cancer Res</source>. <year>2008</year>;<volume>14</volume>(<issue>20</issue>):<fpage>6487</fpage>&#8208;<lpage>6495</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.Ccr-08-1086</pub-id><pub-id pub-id-type="pmid">18927288</pub-id></mixed-citation></ref><ref id="cncr35680-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="cncr35680-cit-0016"><string-name name-style="western"><surname>Vieira</surname><given-names>AF</given-names></string-name>, <string-name name-style="western"><surname>Paredes</surname><given-names>J</given-names></string-name>. <article-title>P&#8208;cadherin and the journey to cancer metastasis</article-title>. <source>Mol Cancer</source>. <year>2015</year>;<volume>14</volume>(<issue>1</issue>):<fpage>178</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12943-015-0448-4</pub-id><pub-id pub-id-type="pmid">26438065</pub-id><pub-id pub-id-type="pmcid">PMC4595126</pub-id></mixed-citation></ref><ref id="cncr35680-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="cncr35680-cit-0017"><string-name name-style="western"><surname>Eisenhauer</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Therasse</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Bogaerts</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1)</article-title>. <source>Eur J Cancer</source>. <year>2009</year>;<volume>45</volume>(<issue>2</issue>):<fpage>228</fpage>&#8208;<lpage>247</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ejca.2008.10.026</pub-id><pub-id pub-id-type="pmid">19097774</pub-id></mixed-citation></ref><ref id="cncr35680-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="cncr35680-cit-0018"><string-name name-style="western"><surname>Vieira</surname><given-names>AF</given-names></string-name>, <string-name name-style="western"><surname>Ricardo</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ablett</surname><given-names>MP</given-names></string-name>, et&#160;al. <article-title>P&#8208;cadherin is coexpressed with CD44 and CD49f and mediates stem cell properties in basal&#8208;like breast cancer</article-title>. <source>Stem Cells</source>. <year>2012</year>;<volume>30</volume>(<issue>5</issue>):<fpage>854</fpage>&#8208;<lpage>864</lpage>. doi:<pub-id pub-id-type="doi">10.1002/stem.1075</pub-id><pub-id pub-id-type="pmid">22389315</pub-id></mixed-citation></ref><ref id="cncr35680-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="cncr35680-cit-0019"><string-name name-style="western"><surname>Shah</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Harrough</surname><given-names>VD</given-names></string-name>, et&#160;al. <article-title>Retreatment with yttrium&#8208;90 ibritumomab tiuxetan in patients with B&#8208;cell non&#8208;Hodgkin's lymphoma</article-title>. <source>Leuk Lymphoma</source>. <year>2007</year>;<volume>48</volume>(<issue>9</issue>):<fpage>1736</fpage>&#8208;<lpage>1744</lpage>. doi:<pub-id pub-id-type="doi">10.1080/10428190701528517</pub-id><pub-id pub-id-type="pmid">17786709</pub-id></mixed-citation></ref><ref id="cncr35680-bib-0020"><label>20</label><mixed-citation publication-type="book" id="cncr35680-cit-0020"><string-name name-style="western"><surname>Lawrence</surname><given-names>TS</given-names></string-name>, <string-name name-style="western"><surname>Ten Haken</surname><given-names>RK</given-names></string-name>, <string-name name-style="western"><surname>Giaccia</surname><given-names>A</given-names></string-name>. <part-title>Principles of radiation oncology</part-title>. In: <person-group person-group-type="editor"><string-name name-style="western"><surname>DeVita</surname><given-names>VT</given-names></string-name></person-group>, <person-group person-group-type="editor"><string-name name-style="western"><surname>Lawrence</surname><given-names>TS</given-names></string-name></person-group>, <person-group person-group-type="editor"><string-name name-style="western"><surname>Rosenberg</surname><given-names>SA</given-names></string-name></person-group>, eds. <source>Cancer: Principles and Practice of Oncology</source>. <edition>8th ed.</edition><publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>; <year>2008</year>:307&#8208;336.</mixed-citation></ref><ref id="cncr35680-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="cncr35680-cit-0021"><string-name name-style="western"><surname>Wong</surname><given-names>JYC</given-names></string-name>, <string-name name-style="western"><surname>Chu</surname><given-names>DZ</given-names></string-name>, <string-name name-style="western"><surname>Yamauchi</surname><given-names>DM</given-names></string-name>, et&#160;al. <article-title>A phase I radioimmunotherapy trial evaluating 90yttrium&#8208;labeled anti&#8208;carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA&#8208;producing malignancies</article-title>. <source>Clin Cancer Res</source>. <year>2000</year>;<volume>6</volume>(<issue>10</issue>):<fpage>3855</fpage>&#8208;<lpage>3863</lpage>.<pub-id pub-id-type="pmid">11051230</pub-id></mixed-citation></ref><ref id="cncr35680-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="cncr35680-cit-0022"><string-name name-style="western"><surname>Gulec</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Cohen</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Pennington</surname><given-names>KL</given-names></string-name>, et&#160;al. <article-title>Treatment of advanced pancreatic carcinoma with 90Y&#8208;clivatuzumab tetraxetan: a phase I single&#8208;dose escalation trial</article-title>. <source>Clin Cancer Res</source>. <year>2011</year>;<volume>17</volume>(<issue>12</issue>):<fpage>4091</fpage>&#8208;<lpage>4100</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.Ccr-10-2579</pub-id><pub-id pub-id-type="pmid">21527562</pub-id><pub-id pub-id-type="pmcid">PMC4048986</pub-id></mixed-citation></ref><ref id="cncr35680-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="cncr35680-cit-0023"><string-name name-style="western"><surname>Sangro</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Gil&#8208;Alzugaray</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Rodriguez</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Liver disease induced by radioembolization of liver tumors: description and possible risk factors</article-title>. <source>Cancer</source>. <year>2008</year>;<volume>112</volume>(<issue>7</issue>):<fpage>1538</fpage>&#8208;<lpage>1546</lpage>. doi:<pub-id pub-id-type="doi">10.1002/cncr.23339</pub-id><pub-id pub-id-type="pmid">18260156</pub-id></mixed-citation></ref><ref id="cncr35680-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="cncr35680-cit-0024"><string-name name-style="western"><surname>Kim</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Jung</surname><given-names>Y</given-names></string-name>. <article-title>Radiation&#8208;induced liver disease: current understanding and future perspectives</article-title>. <source>Exp Mol Med</source>. <year>2017</year>;<volume>49</volume>(<issue>7</issue>):<elocation-id>e359</elocation-id>. doi:<pub-id pub-id-type="doi">10.1038/emm.2017.85</pub-id><pub-id pub-id-type="pmid">28729640</pub-id><pub-id pub-id-type="pmcid">PMC5565955</pub-id></mixed-citation></ref><ref id="cncr35680-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="cncr35680-cit-0025"><string-name name-style="western"><surname>Cortes</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>de Lima</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Dombret</surname><given-names>H</given-names></string-name>, et&#160;al. <article-title>Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia</article-title>. <source>J Hematol Oncol</source>. <year>2020</year>;<volume>13</volume>(<issue>1</issue>):<fpage>137</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13045-020-00975-2</pub-id><pub-id pub-id-type="pmid">33059764</pub-id><pub-id pub-id-type="pmcid">PMC7559451</pub-id></mixed-citation></ref><ref id="cncr35680-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="cncr35680-cit-0026"><string-name name-style="western"><surname>Bodei</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Herrmann</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Sch&#246;der</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Scott</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Lewis</surname><given-names>JS</given-names></string-name>. <article-title>Radiotheranostics in oncology: current challenges and emerging opportunities</article-title>. <source>Nat Rev Clin Oncol</source>. <year>2022</year>;<volume>19</volume>(<issue>8</issue>):<fpage>534</fpage>&#8208;<lpage>550</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41571-022-00652-y</pub-id><pub-id pub-id-type="pmid">35725926</pub-id><pub-id pub-id-type="pmcid">PMC10585450</pub-id></mixed-citation></ref><ref id="cncr35680-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="cncr35680-cit-0027"><string-name name-style="western"><surname>Song</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Sgouros</surname><given-names>G</given-names></string-name>. <article-title>Radioimmunotherapy of solid tumors: searching for the right target</article-title>. <source>Curr Drug Deliv</source>. <year>2011</year>;<volume>8</volume>(<issue>1</issue>):<fpage>26</fpage>&#8208;<lpage>44</lpage>. doi:<pub-id pub-id-type="doi">10.2174/156720111793663651</pub-id><pub-id pub-id-type="pmid">21034423</pub-id><pub-id pub-id-type="pmcid">PMC4337879</pub-id></mixed-citation></ref><ref id="cncr35680-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="cncr35680-cit-0028"><string-name name-style="western"><surname>Rondon</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rouanet</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Degoul</surname><given-names>F</given-names></string-name>. <article-title>Radioimmunotherapy in oncology: overview of the last decade clinical trials</article-title>. <source>Cancers (Basel)</source>. <year>2021</year>;<volume>13</volume>(<issue>21</issue>):<elocation-id>5570</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/cancers13215570</pub-id><pub-id pub-id-type="pmid">34771732</pub-id><pub-id pub-id-type="pmcid">PMC8583425</pub-id></mixed-citation></ref><ref id="cncr35680-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="cncr35680-cit-0029"><string-name name-style="western"><surname>Tempero</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Leichner</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Baranowska&#8208;Kortylewicz</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>High&#8208;dose therapy with 90Yttrium&#8208;labeled monoclonal antibody CC49: a phase I trial</article-title>. <source>Clin Cancer Res</source>. <year>2000</year>;<volume>6</volume>(<issue>8</issue>):<fpage>3095</fpage>&#8208;<lpage>3102</lpage>.<pub-id pub-id-type="pmid">10955789</pub-id></mixed-citation></ref><ref id="cncr35680-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="cncr35680-cit-0030"><string-name name-style="western"><surname>Hanker</surname><given-names>LC</given-names></string-name>, <string-name name-style="western"><surname>Loibl</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Burchardi</surname><given-names>N</given-names></string-name>, et&#160;al. <article-title>The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum&#8208;based therapy</article-title>. <source>Ann Oncol</source>. <year>2012</year>;<volume>23</volume>(<issue>10</issue>):<fpage>2605</fpage>&#8208;<lpage>2612</lpage>. doi:<pub-id pub-id-type="doi">10.1093/annonc/mds203</pub-id><pub-id pub-id-type="pmid">22910840</pub-id></mixed-citation></ref><ref id="cncr35680-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="cncr35680-cit-0031"><string-name name-style="western"><surname>Akhavan</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Yazaki</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Yamauchi</surname><given-names>D</given-names></string-name>, et&#160;al. <article-title>Phase I study of yttrium&#8208;90 radiolabeled M5A anti&#8208;carcinoembryonic antigen humanized antibody in patients with advanced carcinoembryonic antigen producing malignancies</article-title>. <source>Cancer Biother Radiopharm</source>. <year>2020</year>;<volume>35</volume>(<issue>1</issue>):<fpage>10</fpage>&#8208;<lpage>15</lpage>. doi:<pub-id pub-id-type="doi">10.1089/cbr.2019.2992</pub-id><pub-id pub-id-type="pmid">31910346</pub-id><pub-id pub-id-type="pmcid">PMC7044770</pub-id></mixed-citation></ref><ref id="cncr35680-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="cncr35680-cit-0032"><string-name name-style="western"><surname>Al Ojaimi</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Blin</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Lamamy</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Therapeutic antibodies&#8212;natural and pathological barriers and strategies to overcome them</article-title>. <source>Pharmacol Ther</source>. <year>2022</year>;<volume>233</volume>:<elocation-id>108022</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.pharmthera.2021.108022</pub-id><pub-id pub-id-type="pmid">34687769</pub-id><pub-id pub-id-type="pmcid">PMC8527648</pub-id></mixed-citation></ref><ref id="cncr35680-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="cncr35680-cit-0033"><string-name name-style="western"><surname>Navarro&#8208;Teulon</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Lozza</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>P&#232;legrin</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Viv&#232;s</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Pouget</surname><given-names>JP</given-names></string-name>. <article-title>General overview of radioimmunotherapy of solid tumors</article-title>. <source>Immunotherapy</source>. <year>2013</year>;<volume>5</volume>(<issue>5</issue>):<fpage>467</fpage>&#8208;<lpage>487</lpage>. doi:<pub-id pub-id-type="doi">10.2217/imt.13.34</pub-id><pub-id pub-id-type="pmid">23638743</pub-id></mixed-citation></ref><ref id="cncr35680-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="cncr35680-cit-0034"><string-name name-style="western"><surname>Hagiwara</surname><given-names>S</given-names></string-name>. <article-title>Preclinical evaluation of cadherin 3 (CDH3)&#8208;targeted alpha radiopharmaceutical therapy, 225Ac&#8208;PPMX&#8208;T002 for the treatment of solid cancer [abstract]</article-title>. <source>Paper presented at: 37th Annual Congress of the European Association of Nuclear Medicine (EANM)</source>; October 19&#8211;23, <year>2024</year>; Hamburg, Germany.</mixed-citation></ref></ref-list></back></article></pmc-articleset>